Researchers have developed an innovative AI tool designed to enhance risk-based decision-making for localized prostate cancer by analyzing biopsy images. This cutting-edge technology predicts critical factors such as the 10-year risk of distant metastasis and prostate cancer-specific mortality. By utilizing digital pathology images from prostate cancer biopsies, the tool significantly empowers pathologists, providing them with advanced insights into patient outcomes.
Presenting findings at the 2025 American Society of Clinical Oncology Annual Meeting in Chicago, investigators demonstrated that the MMAI algorithm effectively identifies patients with high-risk non-metastatic prostate cancer who would benefit the most from adding abiraterone acetate (Zytiga) with prednisone to standard androgen deprivation therapy. This combination has already improved prognosis for countless men facing advanced prostate cancer. This AI’s application in digital pathology marks a transformative step towards personalized treatment approaches in the fight against prostate cancer.
Source link
